Xiao Qing, Li Guangjun, Li Zhibin, Zhang Xiangbin, Dai Guyu, Bai Sen
Department of Radiotherapy, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu 610041, P.R.China.
Sheng Wu Yi Xue Gong Cheng Xue Za Zhi. 2020 Oct 25;37(5):842-847. doi: 10.7507/1001-5515.202001016.
Patient-specific volumetric modulated arc therapy (VMAT) quality assurance (QA) process is an important component of the implementation process of clinical radiotherapy. The tolerance limit and action limit of discrepancies between the calculated dose and the delivered radiation dose are the key parts of the VMAT QA processes as recognized by the AAPM TG-218 report, however, there is no unified standard for these two values among radiotherapy centers. In this study, based on the operational recommendations given in the AAPM TG-218 report, treatment site-specific tolerance limits and action limits of gamma pass rate in VMAT QA processes when using ArcCHECK for dose verification were established by statistical process control (SPC) methodology. The tolerance limit and action limit were calculated based on the first 25 in-control VMAT QA for each site. The individual control charts were drawn to continuously monitor the VMAT QA process with 287 VMAT plans and analyze the causes of VMAT QA out of control. The tolerance limits for brain, head and neck, abdomen and pelvic VMAT QA processes were 94.56%, 94.68%, 94.34%, and 92.97%, respectively, and the action limits were 93.82%, 92.54%, 93.23%, and 90.29%, respectively. Except for pelvic, the tolerance limits for the brain, head and neck, and abdomen were close to the universal tolerance limit of TG-218 (95%), and the action limits for all sites were higher than the universal action limit of TG-218 (90%). The out-of-control VMAT QAs were detected by the individual control chart, including one case of head and neck, two of the abdomen and two of the pelvic site. Four of them were affected by the setup error, and one was affected by the calibration of ArcCHECK. The results show that the SPC methodology can effectively monitor the IMRT/VMAT QA processes. Setting treatment site-specific tolerance limits is helpful to investigate the cause of out-of-control VMAT QA.
患者特异性容积调强弧形放疗(VMAT)质量保证(QA)流程是临床放射治疗实施过程的重要组成部分。计算剂量与实际 delivered 辐射剂量之间差异的公差限和行动限是美国医学物理学家协会(AAPM)TG - 218报告所认可的VMAT QA流程的关键部分,然而,放疗中心之间这两个值并没有统一的标准。在本研究中,基于AAPM TG - 218报告给出的操作建议,通过统计过程控制(SPC)方法确定了使用ArcCHECK进行剂量验证时VMAT QA流程中特定治疗部位的伽马通过率公差限和行动限。公差限和行动限是根据每个部位的前25次处于控制状态的VMAT QA计算得出的。绘制了个体控制图以持续监测287个VMAT计划的VMAT QA流程,并分析VMAT QA失控的原因。脑、头颈部、腹部和盆腔VMAT QA流程的公差限分别为94.56%、94.68%、94.34%和92.97%,行动限分别为93.82%、92.54%、93.23%和90.29%。除盆腔外,脑、头颈部和腹部的公差限接近TG - 218的通用公差限(95%),所有部位的行动限均高于TG - 218的通用行动限(90%)。通过个体控制图检测到VMAT QA失控情况,包括1例头颈部、2例腹部和2例盆腔部位。其中4例受摆位误差影响,1例受ArcCHECK校准影响。结果表明,SPC方法可有效监测调强放疗(IMRT)/VMAT QA流程。设置特定治疗部位的公差限有助于调查VMAT QA失控的原因。